Semaglutide microdosing care compared: goals, evidence and quoted terms

CoreAge: a longevity description and a qualified shared offer

CoreAge's product page presents compounded semaglutide microdosing as a longevity-focused service, starting at $129 monthly on a 12-month plan. The linked offer page separately presents semaglutide at $79 and tirzepatide at $129, with a footer tying starting prices to a twelve-month prepaid plan. A reader therefore needs the actual semaglutide quote and terms, rather than assuming all three numbers describe the same purchase.

The page advertises no membership and ongoing access. Those service claims do not verify an exact-compound longevity outcome. Our CoreAge review records the remaining formulation, billing and evidence questions together, without using one answered question to excuse another.

SuperHealthy Rx: $199 one-month offer; confirm availability

The dedicated semaglutide microdosing page lists $199 for a one-month supply and describes an online assessment followed by medical review. That is a separate page from the regular GLP-1 promotional offer; its price should not be substituted with the $85 semaglutide headline.

The public page contains availability language and generic dual-hormone copy. Semaglutide should not be relabeled as a dual GLP-1/GIP medicine on that basis. Confirm whether the named program can currently accept an intake and identify the actual preparation before paying.

Read the SuperHealthy Rx review and official details.

3. Likeness Rx — GLP-1 weight care

A clear buying decision starts with the selected supply period. Likeness Rx offers online access to compounded semaglutide and tirzepatide. Its public page lists semaglutide from $79/month; tirzepatide from $129/month.

The lowest monthly equivalents accompany 12-month subscriptions: $948 for semaglutide or $1,548 for tirzepatide. One-month plans are $139 and $199. The page says the selected term renews automatically; check the amount due and cancellation date.

The public site describes licensed-provider review, shipping after approval and care-team messaging. Those are service statements rather than measured response times.

These are provider-published terms checked October 4, 2026. Prescription approval is conditional. Compounded medications are not FDA-approved; we have not tested the treatment, pharmacy fulfillment or patient outcomes.

Read our Likeness Rx review or the current product details.

AgelessRx: research interest is distinct from research results

The AgelessRx product record describes a compounded semaglutide program that may include glycine. Its $99 monthly starting figure applies to a four-month plan billed in full, followed by a displayed $159 monthly figure. The page also describes unlimited messaging, check-ins and a prescription assessment. The supplied formulation and actual subscription terms still belong to the individual care record.

An AgelessRx trial update, dated September 2, says enrollment has concluded but final participants must complete the protocol before analysis. That is evidence of a sponsor's stated research activity, not completed efficacy results. The AgelessRx review also distinguishes its customer survey from that planned analysis.

Noom: identify the program before interpreting its price

Noom's Microdose page currently names both compounded semaglutide and tirzepatide offerings. It describes a package with clinical care, medication if prescribed and behavioral support. That makes the specific medicine and selected program essential fields, rather than details that can be inferred from the Noom name.

The page advertises an initial $79 offer with distinct subscription and medicine-supply periods, followed by qualified renewal pricing. Its pricing directory also shows a $49 introductory figure alongside $79, so a current personal quote is not established by copying the lowest visible number. See the Noom review for the source-specific pricing and survey limitations.

The approved-product reference answers a narrower question

The Wegovy prescribing information defines approved uses and reports evidence for particular populations and formulations. It is a useful reference precisely because those boundaries are specified. It does not make every semaglutide-containing compound equivalent, or turn healthy-aging language into an approved indication.

Our study-population guide follows who was enrolled, what was compared and what was measured. A weight outcome does not establish a longevity outcome. A change observed in a high-risk group does not establish the same benefit in people outside that group. Cross-provider marketing cannot fill those gaps by referring generally to a well-studied ingredient.

The same word does not establish the same safety profile

These providers all use lower-dose language, but it should not be read as a common validated protocol. FDA's current concerns include measurement-related errors with compounded semaglutide, product-quality concerns and different salt forms. The warning is relevant to the quality of the clinical and pharmacy discussion; it is not a finding that a particular reviewed provider supplied a defective product.

Important approved-product risks still require professional attention. The label includes serious gastrointestinal effects and complications involving the pancreas, gallbladder and kidney, among other precautions. No price tier, online questionnaire or testimonial establishes that these issues are irrelevant to a particular person.

Compare who owns the follow-up, not just access to messaging

Messaging, coaching and clinical interpretation are different services. A useful service description identifies who responds to administrative questions, who makes prescribing decisions, and how progress or new symptoms reach that clinician. A program may advertise ongoing support while leaving actual response times or the division of responsibilities unstated.

The reviewed pages do not allow us to test those handoffs. They also do not establish every laboratory charge or state-specific restriction for an individual plan. Comparing offers means keeping unknowns visible rather than awarding points for promises that were not observed. The meaning of microdosing remains a separate question from whether a service has a convenient communication channel.

A useful comparison ends with bounded conclusions

CoreAge's shared offer needs to be reconciled with its semaglutide product page. AgelessRx's survey and trial announcement answer different evidence questions. Noom's program, medication and renewal terms must be identified together. These findings support document questions; they do not establish a universal best provider or tell a reader which treatment to choose.

Compounded-drug status is another independent boundary: FDA has not approved the finished compounds. Our pharmacy and salt-form guide keeps that distinction separate from legitimate questions about an individual prescription. The appropriate clinical discussion can include approved-product care and nonmedication assessment, without assuming that purchase of a microdose program is the necessary next step.

Compare the program before comparing the headline

The Hims review follows named branded medicine offers and their membership conditions. The Ro review separates the care subscription from medication costs and examines what program-level reports can establish. These services belong in a broader care comparison, but their inclusion does not verify that they provide the compounded microdosing program advertised elsewhere in this article.

The WeightWatchers Clinic review considers behavioral support, care commitments and the limits of observational results. The LifeMD review examines another clinical subscription with its own eligibility and refund conditions. Comparing each service on its actual published terms is more informative than assuming a medicine name makes the programs equivalent. A payment commitment, clinical assessment and eventual prescription remain different stages with different questions to resolve.